Carlos Requena

Carlos Requena

Auto-generated profile, based on publicly available information

Carlos Requena

A Centro de Investigaciones Biológicas (CIB-CSIC), C/Ramiro de Maeztu , Madrid , Spain

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 May 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
IPIgnacio Ponzoni
Ignacio Ponzoni
VSVíctor Sebastián-Pérez
Víctor Sebastián-Pérez
CRCarlos Requena-Triguero
Carlos Requena-Triguero
CRCarlos Roca
Carlos Roca
MMMaría J. Martínez
María J. Martínez
NCNuria E. Campillo
Nuria E. Campillo
Quantitative structure–activity relationship modeling using machine learning techniques constitutes a complex computational problem, where the identification of the most informative molecular descriptors for predicting a specific target property plays a critical role. Two main general approaches can be used for this modeling procedure: feature selection and feature learning. In this paper, a performance comparative study of two state-of-art methods related to these two approaches is carried out. In particular, regression and classification models for three different issues are inferred using both methods under different experimental scenarios: two drug-like properties, such as blood-brain-barrier and human intestinal absorption, and enantiomeric excess, as a measurement of purity used for chiral substances. Beyond the contrastive analysis of feature selection and feature learning methods as competitive approaches, the hybridization of these strategies is also evaluated based on previous results obtained in material sciences. From the experimental results, it can be concluded that there is not a clear winner between both approaches because the performance depends on the characteristics of the compound databases used for modeling. Nevertheless, in several cases, it was observed that the accuracy of the models can be improved by combining both approaches when the molecular descriptor sets provided by feature selection and feature learning contain complementary information.

1 January 2018 in Journal of Enzyme Inhibition and Medicinal Chemistry
Verified
Journal Article
Open access
CRCarlos Roca
Carlos Roca
CRCarlos Requena
Carlos Requena
VSVíctor Sebastián-Pérez
Víctor Sebastián-Pérez
SMSony Malhotra
Sony Malhotra
CRChris Radoux
Chris Radoux
NCNuria E. Campillo
Nuria E. Campillo
Allosteric sites on proteins are targeted for designing more selective inhibitors of enzyme activity and to discover new functions. Acetylcholinesterase (AChE), which is most widely known for the hydrolysis of the neurotransmitter acetylcholine, has a peripheral allosteric subsite responsible for amyloidosis in Alzheimer’s disease through interaction with amyloid β-peptide. However, AChE plays other non-hydrolytic functions. Here, we identify and characterise using computational tools two new allosteric sites in AChE, which have allowed us to identify allosteric inhibitors by virtual screening guided by structure-based and fragment hotspot strategies. The identified compounds were also screened for in vitro inhibition of AChE and three were observed to be active. Further experimental (kinetic) and computational (molecular dynamics) studies have been performed to verify the allosteric activity. These new compounds may be valuable pharmacological tools in the study of non-cholinergic functions of AChE.

1 October 2017 in European Journal of Medicinal Chemistry
Verified
Journal Article
Open access
TCTalita P.C. Chierrito
Talita P.C. Chierrito
SPSusimaire Pedersoli-Mantoani
Susimaire Pedersoli-Mantoani
CRCarlos Roca
Carlos Roca
CRCarlos Requena
Carlos Requena
VSVictor Sebastian-Perez
Victor Sebastian-Perez
ICIvone Carvalho
Ivone Carvalho
The lack of an effective treatment for Alzheimer' disease (AD), an increasing prevalence and severe neurodegenerative pathology boost medicinal chemists to look for new drugs. Currently, only acethylcholinesterase (AChE) inhibitors and glutamate antagonist have been approved to the palliative treatment of AD. Although they have a short-term symptomatic benefits, their clinical use have revealed important non-cholinergic functions for AChE such its chaperone role in beta-amyloid toxicity. We propose here the design, synthesis and evaluation of non-toxic dual binding site AChEIs by hybridization of indanone and quinoline heterocyclic scaffolds. Unexpectely, we have found a potent allosteric modulator of AChE able to target cholinergic and non-cholinergic functions by fixing a specific AChE conformation, confirmed by STD-NMR and molecular modeling studies. Furthermore the promising biological data obtained on human neuroblastoma SH-SY5Y cell assays for the new allosteric hybrid 14, led us to propose it as a valuable pharmacological tool for the study of non-cholinergic functions of AChE, and as a new important lead for novel disease modifying agents against AD.